EGFR and non-small cell lung carcinoma: Erlotinib alone treatment could raise the percentage of apoptotic cells in HCC827 xenografts tumors rather than HCC2279 xenografts tumors (Figure 7B, 7C), suggesting that NSCLC xenografts tumors expressing EGFR-mutant and harboring the BIM deletion polymorphism are also resistant to erlotinib-induced apoptosis in vivo.